Breaking News Instant updates and real-time market news.

2018-02-13 05:03:05

CELG

Celgene

$91.51

-1 (-1.08%)

05:03

02/13/18

02/13

05:03

02/13/18

05:03

Celgene upgraded to Overweight from Equal Weight at Barclays

Barclays analyst Geoff Meacham upgraded Celgene to Overweight with an unchanged price target of $105. The analyst remains concerned about Revlimid concentration risk long-term, but says the current valuation largely reflects the risk. Since the highs in October 2017, the stock has dropped $55 per share, Meacham tells investors in a research note. He notes Celgene's risk/reward profile based on his net present value analysis yields an "attractive upside case."

16

Feb

21

Feb

25

Mar

30

May

CELGCelgene

$91.51

-1 (-1.08%)

02/09/18

PIPR

02/09/18NO CHANGEPIPR

Piper Jaffray reiterates Outperform on Crispr after CSO departure

Piper Jaffray analyst Edward Tenthoff reiterated an Outperform rating and $39 price target on Crispr Therapeutics, despite Crispr trading down over 13% on news that Dr. Bill Lundberg is stepping down as Chief Scientific Officer and Celgene (CELG) has reduced its stake in the company to 6.1% from 8.0%. Tenthoff said he remains focused on Crispr's "therapeutic opportunity with first-in-man CTX001 Beta thalassemia and potentially sickle cell disease data this year."

Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics (IOVA) to $23 following feedback from a "prominent cell therapy expert" late last week. The expert described expanding capacity for Gilead's (GILD) Yescarta, skepticism on Celgene (CELG) and Juno Therapeutics' (JUNO) claims around broad outpatient CAR-T opportunity for JCAR17, and a preference for tumor infiltrating lymphocyte therapeutics from Iovance for solid tumors over T-Cell receptor therapeutics being developed by a large number of companies, Birchenough tells investors in a research note. He reiterates Outperform ratings on both Iovance and Gilead.

01/24/18

LEHM

01/24/18DOWNGRADETarget $87LEHMEqual Weight

Juno Therapeutics downgraded to Equal Weight from Overweight at Barclays

Barclays analyst Gena Wang downgraded Juno Therapeutics (JUNO) to Equal Weight following the proposed acquisition by Celgene (CELG). The analyst believes the offer price of $87 per share fully reflects the value of the stock and sees a low probability of other companies trying to outbid the price. She raised her price target for Juno shares to $87 from $55.

01/23/18

LEER

01/23/18DOWNGRADETarget $87LEERMarket Perform

Juno Therapeutics downgraded to Market Perform from Outperform at Leerink

Leerink analyst Michael Schmidt downgraded Juno Therapeutics (JUNO) to Market Perform from Outperform and raised his price target on the shares to $87 from $56 after Celgene (CELG) announced that it has signed a definitive merger agreement to acquire the company.

Nuance has ceased development this month of the Swype feature for both iOS and Android, six years after it acquired the company behind the keyboard app for roughly $100M, the Verge reports, citing an emailed statement. Nuance said that it would discontinue support of the keyboard app and shift focus to other products, the report says. "The core technology behind Swype will continue to be utilized and improved upon across other Nuance offerings - and integrated into our broader AI-powered solutions - most notably in Android-based keyboard solutions for our automotive customers," the company said, according to the Verge. Reference Link

Baskin-Robbins, a Dunkin' Brands company, announced its continued expansion in the Toronto, Ontario market with the signing of four new store development agreements with three existing franchise groups. The first Baskin-Robbins shop under these new agreements is scheduled to open in 2019. Currently, there are more than 80 Baskin-Robbins locations throughout the greater Toronto area, and growing the brand there remains a top priority for Baskin-Robbins in 2018 and beyond.

Reports Q4 revenue $369.0M, consensus $340.56M. Q4 Adjusted EBITDA was $110.5M for the three months ended December 31, 2017, up 294% sequentially from $28.0M for the three months ended September 30, 2017 and up 691% from $14.0M for the three months ended December 31, 2016.

UP AFTER EARNINGS: Bandwidth (BAND), up 12%... Avis Budget (CAR), up 8.3%... Mindbody (MB), up 8%... SailPoint Technologies (SAIL), up 7.1%... Stamps.com (STMP), up 6.5%... Gulfport Energy (GPOR), up 5.8%... Synopsys (SNPS), up 4.4%... Parsley Energy (PE), up 3.5%... Pandora (P), up 2.5%. ALSO HIGHER: Mellanox Technologies (MLNX), up 10.4% after it updated its first quarter outlook and announced that CFO Jacob Shulman is stepping down. DOWN AFTER EARNINGS: Roku (ROKU), down 22%... Applied Optoelectronics (AAOI), down 12.5%... Stericycle (SRCL), down 9.2%... Castlight Health (CSLT), down 9.1%... Ultra Clean (UCTT), down 8.3%... Trinity Industries (TRN), down 5.6%... Sturm, Ruger (RGR), down 4.9%... CyrusOne (CONE), down 1.7%. ALSO LOWER: Advaxis (ADXS), down 13.2% after it announced a common stock offering... GW Pharmaceuticals (GWPH), down 5.5% after it said that its Phase 2a study of GWP42006 did not meet its primary endpoint... OneMain Holdings (OMF), down 2% after it announced an offering of 4.18M shares of common stock for holders.